Hypolipidemic Activity of Sesquiterpene Lactones and their Derivatives
DOI:
https://doi.org/10.3889/oamjms.2023.11650Keywords:
Hypolipidemia, Sesquiterpene γ-lactones and their derivatives, Molecular docking, “Target ligand”, In silico, Gene expression, Lipid metabolism enzymes, in vitroAbstract
BACKGROUND: Despite the available range of lipid-lowering drugs, mainly of synthetic origin, the problem of atherosclerosis therapy and its manifestations remain unresolved. Bioinformatics methods, in particular molecular docking, are considered as a promising direction in terms of developing effective original lipid-lowering drugs. Today, as a promising source of natural lipid-lowering agents, it is advisable to consider natural terpenoids, namely sesquiterpene lactones, which are distinguished by a wide range of pharmacological activity. This article presents the results of a virtual and biological screening of the lipid-lowering activity of sesquiterpene γ-lactones and their chemically modified derivatives.
AIM: The aim is to evaluate the lipid-lowering properties of samples of sesquiterpene γ-lactones and their derivatives by virtual and biological screening methods.
METHODS: Molecular modeling of the binding energy of the “ligand-target” complex (docking). Molecular docking of the lipid-lowering activity of sesquiterpene γ-lactones and their derivatives was performed using the Glide program from the developer of the Schrodinger Small-Molecule Drug Discovery package using the Extra Precision algorithm (https://www.schrodinger.com/glide). The effect of sesquiterpene lactones on the expression of genes for key enzymes of lipid metabolism in the liver was studied in an in vivo model of hyperlipidemia caused by an atherogenic diet.
CONCLUSION: Virtual screening of the lipid-lowering activity of sesquiterpene γ-lactones and their derivatives by molecular docking revealed a number of promising compounds (matricin, matricarin, grossmisin oxime, austricin oxime, 5β (H)-austricin) receptor interactions on the enzyme system cholesterol 7α-hydroxylase (CYP7A1). New mechanisms of lipid-lowering activity for sesquiterpene γ-lactones were proposed, which were established in the study of gene expression of key enzymes of lipid metabolism in the liver in a model of hyperlipidemia caused by an atherogenic diet in rats under in vivo conditions.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ramsey SA, Gold ES, Aderem AA. A system biology approach to understanding atherosclerosis. EMBO Mol Med. 2010;3(2):79-89. https://doi.org/10.1002/emmm.201000063 PMid:20201031
Kumar D, Parcha V, Maithani A, Dhulia I. Effect and evaluation of antihyperlipidemic activity guided isolated fraction from total methanol extract of Salvadora oleoides (Decne.) in triton WR-1339 induced hyperlipidemic rats. Pharmacogn Mag. 2012;32(8):314-8. https://doi.org/10.4103/0973-1296.103663 PMid:24082636
Hall IH, Lee KH, Starnes CO, Muraoka O, Sumida Y, Waddel TG. Antihyperlipidemic activity of Sesquiterpene lactones and related compounds. J Pharm Sci. 1980;69(6):694-7. https://doi.org/10.1002/jps.2600690622 PMid:7205585
Rodnova EA, Ivanov VV, Chuchalin VS, Ledyukova SI, Ratkin AV, Rakhimova BB, et al. Influence of leucomisin, a sesquiterpene lactone of Artemisia leucodes Schrenk, on lipolysis in isolated rat adipocytes. Bull New Med Technol. 2012;19(4):114-5.
Kirmukov AG, Aizikov MI, Rasulova SA, Sidiakin GP, Shamianov ID, Malikov VM. The angioprotector and hypolipemic activity of leukomizin in experimental atherosclerosis. Farmakol Toksikol. 1991;54(3):35-7. PMid:1915817
Asgary S, Naderi GH, Sarrafzadegan N, Mohammadifard N, Mostafavi S, Vakili R. Antihypertensive and antihyperlipidemic effects of Achillea wilhelmsii. Drugs Exp Clin Res. 2000;26(3):89-93. PMid:10941601
Acevedo CH, Scotti L, Alves MF, Diniz MF, Scotti MT. Computer- aided drug design using Sesquiterpene lactones as sources of new structures with potential activity against infectious neglected diseases. Molecules. 2017;79(22):79. https://doi.org/10.3390/molecules22010079 PMid:28054952
Adekenov SM, Dairov AK, Spiwok V, Seidakhmetova RB. Molecular docking of arglabin and its derivatives and their biological activity. Czech Chem Soc Symp Ser. 2015;13(3-4):185-95.
Schwarz O, Jakupovic S, Ambrosi HD, Haustedt LO, Mang C, Muller-Kuhrt L. Natural products in parallel chemistry-novel 5-lipoxygenase inhibitors from BIOS-based libraries starting from alpha-santonin. J Comb Chem. 2007;9(6):1104-13. https://doi.org/10.1021/cc700098t PMid:17850107
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-49. https://doi.org/10.1021/jm0306430 PMid:15027865
Perspicace S, Rufer AC, Thoma R, Mueller F, Hennig M, Ceccarelli S, et al. Isothermal titration calorimetry with micelles: Thermodynamics of inhibitor binding to carnitine palmitoyltransferase 2 membrane protein. FEBS Open Bio. 2013;3:204-11. https://doi.org/10.1016/j.fob.2013.04.003 PMid:23772395
Tempel W, Grabovec I, MacKenzie F, Dichenko YV, Usanov SA, Gilep AA, et al. Structural characterization of human cholesterol 7α-hydroxylase. J Lipid Res. 2014;55(9):1925-32. https://doi.org/10.1194/jlr.M050765 PMid:24927729
Sarver RW, Bill E, Bolton G, Bratton LD, Caspers NL, Dunbar JB, et al. Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem. 2008;51(13):3804-13. https://doi.org/10.1021/jm7015057 PMid:18540668
Samanta S, Situ AJ, Ulmer TS. Structural characterization of the regulatory domain of brain carnitine palmitoyltransferase 1. Biopolymers. 2014;101(4):398-405. https://doi.org/10.1002/bip.22396 PMid:24037959
Hunkeler M, Stuttfeld E, Hagmann A, Imseng S, Maier T. The dynamic organization of fungal acetyl-CoA carboxylase. Nat Commun. 2016;7:1196. https://doi.org/10.1038/ncomms11196 PMid:27073141
Piper DE, Romanov WG, Gunawardane RN, Fordstrom P, Masterman S, Pan O, et al. The high-resolution crystal structure of human LCAT. J Lipid Res. 2015;56(9):1711-9. https://doi.org/10.1194/jlr.M059873 PMid:26195816
Mironov AN. Guidelines for Conducting Preclinical Studies of Drugs. Part One. Moscow: Grif I K; 2012. p. 944.
Kopf T, Schaefer HL, Troetzmueller M, Koefeler H, Broenstrup M, Konovalova T, et al. Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats. PLoS One. 2014;9(9):e106849. https://doi.org/10.1371/journal.pone.0106849 PMid:25198467
Ferreira ES, Silva MA, Demonte A, Neves VA. β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats. Lipids Health Dis. 2012;11(11):11. https://doi.org/10.1186/1476-511X-11-11 PMid:22243700
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45. https://doi.org/10.1093/nar/29.9.e45 PMid:11328886
Zhang DM, Jiao RQ, Kong LD. High dietary fructose: Direct or indirect dangerous factors disturbing tissue and organ functions. Nutrients. 2017;9(4):335. https://doi.org/10.3390/nu9040335 PMid:28353649
DiNicolantonio JJ, O’Keefe JH, Lucan SC. Added fructose: A principal driver of Type 2 diabetes mellitus and its consequences. Mayo Clin Proc. 2015;90(3):372-81. https://doi.org/10.1016/j.mayocp.2014.12.019 PMid:25639270
Rashwan AS, El-Beltagy MA, Saleh SY, Ibrahim IA. Potential role of cinnamaldehyde and costunolide to counteract metabolic syndrome induced by excessive fructose consumption. Beni Suef Univ J Basic Appl Sci. 2019;8(1):17. https://doi.org/10.1186/s43088-019-0025-9
Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124(1):35-46. https://doi.org/10.1016/j.cell.2005.12.022 PMid:16413480
Wang J, Wang S, Zhang X, Hu L, Shi P. Artemisinin reduces lipid accumulation in hepatocytes by inhibition of CD36 expression. Indian J Pharm Educ Res. 2017;51(3):393-400.
Huang Z, Zhou X, Nicholson AC, Gotto AM Jr., Hajjar DP, Han J. Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor. Br J Pharmacol. 2008;155(4):596-605. https://doi.org/10.1038/bjp.2008.331 PMid:18852694
Wang YM, Zhang B, Xue Y, Li ZJ, Wang JF, Xue CH, et al. The mechanism of dietary cholesterol effects on lipids metabolism in rats. Lipids Health Dis. 2010;9:4. https://doi. org/10.1186/1476-511X-9-4 PMid:20070910
Adekenov SM, Rodnova EA, Ivanov VV, Chuchalin VS, Ledyukova SI. On the mechanism of the hypocholesterolemic action of the sesquiterpene lactone leucomisin. Pharm Bull. 2012;2-3:50-3.
Lee MK, Moon SS, Lee SE, Bok SH, Jeong TS, Park YB, et al. Naringenin 7-O-cetyl ether as inhibitor of HMG-CoA reductase and modulator of plasma and hepatic lipids in high cholesterol- fed rats. Bioorg Med Chem. 2003;11(3):393-8. https://doi.org/10.1016/s0968-0896(02)00441-8 PMid:12517434
Burnett JR, Telford DE, Barrett PH, Huff MW. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Biochim Biophys Acta. 2005;1738(1-3):10-8. https://doi.org/10.1016/j.bbalip.2005.11.010 PMid:16427354
Roberts CK, Liang K, Barnard RJ, Kim CH, Vaziri ND. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. Kidney Int. 2004;66(4):1503-11. https://doi.org/10.1111/j.1523-1755.2004.00914.x PMid:15458444
Russel DW, Setchell KD. Bile acid biosynthesis. Biochemistry. 1992;31(20):4737-49. https://doi.org/10.1021/bi00135a001 PMid:1591235
Chen ZY, Jiao R, Ma KY. Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem. 2008;56(19):8761-73. https://doi.org/10.1021/jf801566r PMid:18778072
Fu ZD, Cui JY, Klaassen CD. Atorvastatin induces bile acid- synthetic enzyme CYP7A1 by suppressing FXR signaling in both liver and intestine in mice. J Lipid Res. 2014;55(12):2576-86. https://doi.org/10.1194/jlr.M05312 PMid:25278499
Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21(11):1840-5. https://doi.org/10.1161/hq1101.098228 PMid:11701475
Roglans N, Vasquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, et al. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol. 2004;59(12):855-61. https://doi.org/10.1007/s00228-003-0704-1 PMid:14685799
Gbaguidi GF, Agellon LB. The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer. Nucleic Acids Res. 2004;32(3):1113-21. https://doi.org/10.1093/nar/gkh260 PMid:14960721
Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: Biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5-6):495-520. https://doi.org/10.1016/j.mam.2004.06.004 PMid:15363638
Downloads
Published
How to Cite
License
Copyright (c) 2023 Sergazy Adekenov, Václav Mareška, Vladimir Ivanov, O. V. Maslova, Aidos Doskaliyev, M. Z. Shaidarov, Vojtech Spiwok (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
Funding data
-
Ministry of Education and Science
Grant numbers the grant project AP09259740 “Study of the “structure-activity” relationship and pharmacological study of new plant metabolites and their derivatives”
